TABLE 3

Biodistribution of ^99mTc(EDDA)-HYNIC-AocNle-CycMSH_hex in B16/F1 Melanoma–Bearing C57 Mice

Tissue	0.5 h	2 h	4 h	24 h	2-h NDP blockade	2-h L-lys coinjection
%ID/g
Tumor	23.44 ± 3.37	22.8 ± 1.71	22.17 ± 5.93	7.13 ± 0.99	1.26 ± 0.59^*	25.85 ± 6.8
Brain	0.17 ± 0.07	0.05 ± 0.03	0.02 ± 0.02	0.01 ± 0.01	0.03 ± 0.01	0.03 ± 0.01
Blood	2.98 ± 1.77	0.40 ± 0.14	0.30 ± 0.14	0.09 ± 0.03	0.82 ± 0.15	0.18 ± 0.13
Heart	1.75 ± 0.31	0.23 ± 0.08	0.13 ± 0.09	0.07 ± 0.02	0.32 ± 0.09	0.14 ± 0.01
Lung	4.06 ± 1.60	0.52 ± 0.20	0.50 ± 0.19	0.14 ± 0.02	0.91 ± 0.06	0.59 ± 0.06
Liver	3.19 ± 0.39	1.09 ± 0.33	1.26 ± 0.60	0.36 ± 0.01	1.22 ± 0.12	1.22 ± 0.15
Spleen	0.94 ± 0.72	0.30 ± 0.13	0.32 ± 0.13	0.05 ± 0.04	0.17 ± 0.11	0.22 ± 0.09
Stomach	2.52 ± 0.22	1.07 ± 0.10	0.73 ± 0.21	0.11 ± 0.02	0.56 ± 0.10	0.97 ± 0.36
Kidneys	19.65 ± 7.36	6.92 ± 1.40	6.10 ± 0.72	1.05 ± 0.07	6.05 ± 1.13	4.64 ± 0.48^*
Muscle	0.43 ± 0.14	0.04 ± 0.03	0.04 ± 0.03	0.02 ± 0.01	0.06 ± 0.05	0.07 ± 0.06
Pancreas	0.97 ± 0.40	0.19 ± 0.14	0.44 ± 0.64	0.06 ± 0.03	0.31 ± 0.10	0.06 ± 0.02
Bone	1.09 ± 0.28	0.15 ± 0.09	0.19 ± 0.15	0.12 ± 0.07	0.30 ± 0.08	0.33 ± 0.30
Skin	3.62 ± 0.35	0.46 ± 0.10	0.37 ± 0.11	0.15 ± 0.05	0.45 ± 0.06	0.54 ± 0.10
%ID
Intestines	2.43 ± 0.31	1.85 ± 0.51	3.43 ± 0.76	0.32 ± 0.09	1.85 ± 0.42	1.64 ± 0.40
Urine	60.22 ± 4.46	88.46 ± 2.23	84.47 ± 4.80	96.84 ± 1.17	91.29 ± 0.70	88.11 ± 1.90
T/NT
Liver	7.34	20.86	17.62	20.05	1.03	21.19
Kidney	1.19	3.29	3.63	6.78	0.21	5.57
Lung	5.78	43.77	44.51	52.05	1.39	44.16
Muscle	54.62	527.80	502.79	450.68	21.12	392.26
Blood	7.87	57.59	74.61	82.89	1.54	139.85
Skin	6.47	49.13	59.92	47.99	2.82	47.44

↵* P < 0.05 for differences in tumor and kidney uptake between ^99mTc(EDDA)-HYNIC-AocNle-CycMSH_hex with and without peptide blockade, and with and without L-lys coinjection at 2 h after injection.
T/NT = tumor–to–normal-tissue uptake ratio.
Two-hour data are cited from Table 2 for comparison. Data are %ID/g or %ID (mean ± SD, n = 5).